90 likes | 98 Views
Explore the efficacy, safety, and patient characteristics of Daclatasvir, Sofosbuvir, and Ribavirin in treating HCV GT3 with advanced liver disease. Results and conclusions from the ALLY-3+ Trial. Presented by Leroy V. et al. in Hepatology 2016.
E N D
Phase 3 Treatment-Naïve and Treatment-Experienced Daclatasvir + Sofosbuvir + RBV in GT3with Advanced Liver DiseaseALLY-3+ Study Leroy V, et al. Hepatology 2016;63:1430-41.
Daclatasvir + Sofosbuvir + RBV for HCVGT 3 Advanced Liver DiseaseALLY-3+ Trial: Study Features Source: Leroy V, et al. Hepatology 2016;63:1430-41.
Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver DiseaseALLY-3+ Trial: Design 0 12 24 16 28 Week DCV + SOF + RBV N = 24 SVR12 DCV + SOF + RBV N = 26 SVR12 Drug DosingDaclatasvir (DCV): 60 mg once dailySofosbuvir (SOF: 400 mg once dailyRibavirin (RBV): GT1, given weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Source: Leroy V, et al. Hepatology 2016;63:1430-41.
Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver Disease ALLY-3+ Trial: Patient Characteristics IFN=peginterferon, SOF=sofosbuvir, DCV=daclatasvir, RAVs=resistance-associated variants Source: Leroy V, et al. Hepatology 2016;63:1430-41.
Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver DiseaseALLY-3+ Trial: Results ALLY-3+: SVR12by Treatment Arm 21/24 24/26 45/50 SVR12 rates determined by intent-to-treat analysis Source: Leroy V, et al. Hepatology 2016;63:1430-41.
Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver DiseaseALLY-3+ Trial: Results ALLY-3+: SVR12 by Cirrhosis Status 73/75 32/34 11/19 9/13 31/36 26/30 6/6 15/18 14/16 8/8 16/18 12/14 14/14 SVR12 rates determined by intent-to-treat analysis Source: Leroy V, et al. Hepatology 2016;63:1430-41.
Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver Disease ALLY-3+ Trial: Safety Source: Leroy V, et al. Hepatology 2016;63:1430-41.
Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver Disease ALLY-3+ Trial: Conclusion Source: Leroy V, et al. Hepatology 2016;63:1430-41.
This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.